FDA Case-By-Case Approach To Class I Exempt SUDs Needs Change - MDMA
This article was originally published in The Gray Sheet
Executive Summary
FDA should articulate a policy on reprocessing Class I 510(k)-exempt single-use devices rather than taking action only when problems with a particular product are brought to the agency's attention, according to the Medical Device Manufacturers Association.
You may also be interested in...
Device Reuse: 510(k) Exemptions Terminated, Validation Guidance Awaited
FDA is retaining its 510(k)-exempt status for non-electric biopsy forceps, despite a further layer of scrutiny afforded by the Medical Device User Fee & Modernization Act
Device Reuse: 510(k) Exemptions Terminated, Validation Guidance Awaited
FDA is retaining its 510(k)-exempt status for non-electric biopsy forceps, despite a further layer of scrutiny afforded by the Medical Device User Fee & Modernization Act
Third-Party Reviews Should Be Used Only If Expertise Is Lacking – MDMA
The Medical Device Manufacturers Association is seeking to toughen FDA device reform legislation to prevent outside expert reviews of PMAs from occurring unless the agency lacks resources to conduct the reviews in-house